Cargando…

Co-Delivery of Paclitaxel Prodrug, Gemcitabine and Porphine by Micelles for Pancreatic Cancer Treatment via Chemo-Photodynamic Combination Therapy

Pancreatic carcinoma is an aggressive subtype of cancer with poor prognosis, known for its refractory nature. To address this challenge, we have established a stable nanoplatform that combines chemotherapy with photodynamic therapy (PDT) to achieve better curative efficacy. First, we designed and sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Qiwei, Ma, Xiaodong, Zhou, Wenhui, Yu, Rong, Rosenholm, Jessica M., Tian, Weizhong, Zhang, Lirong, Wang, Dongqing, Zhang, Hongbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9698062/
https://www.ncbi.nlm.nih.gov/pubmed/36365099
http://dx.doi.org/10.3390/pharmaceutics14112280
_version_ 1784838722309586944
author Wu, Qiwei
Ma, Xiaodong
Zhou, Wenhui
Yu, Rong
Rosenholm, Jessica M.
Tian, Weizhong
Zhang, Lirong
Wang, Dongqing
Zhang, Hongbo
author_facet Wu, Qiwei
Ma, Xiaodong
Zhou, Wenhui
Yu, Rong
Rosenholm, Jessica M.
Tian, Weizhong
Zhang, Lirong
Wang, Dongqing
Zhang, Hongbo
author_sort Wu, Qiwei
collection PubMed
description Pancreatic carcinoma is an aggressive subtype of cancer with poor prognosis, known for its refractory nature. To address this challenge, we have established a stable nanoplatform that combines chemotherapy with photodynamic therapy (PDT) to achieve better curative efficacy. First, we designed and synthesized a disulfide-bonded paclitaxel (PTX)-based prodrug, which was further mixed with gemcitabine (GEM) and photosensitizer THPP in an optimized ratio. Subsequently, the mixture was added dropwise into amphiphilic polymer DSPE-PEG water solution to form micelles composed of DSPE-PEG nanoparticles (TPG NPs). The TPG NPs were around 135 nm, and showed great ability of DTT stimulated release of PTX and GEM. Moreover, the TPG NPs can be efficiently uptaken by pancreatic cancer PANC-1 cells and effectively kill them, especially when combined with 650 nm laser irradiation. Finally, the TPG NPs have shown enhanced long-term circulation ability and also exhibited efficient anti-tumor activity in combination with 650 nm laser irradiation in a pancreatic cancer mouse model. In summary, the designed TPG NPs possesses great potential for co-delivery of paclitaxel prodrug, GEM and THPP, which enables combined chemo-photodynamic therapy for cancer treatment. In addition, the stimulated release of PTX prodrug and GEM also allows for better targeting of tumor cells and the increased therapeutic effect against cancer cells. Overall, the TPG NPs can serve as a good candidate for pancreatic cancer treatment.
format Online
Article
Text
id pubmed-9698062
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96980622022-11-26 Co-Delivery of Paclitaxel Prodrug, Gemcitabine and Porphine by Micelles for Pancreatic Cancer Treatment via Chemo-Photodynamic Combination Therapy Wu, Qiwei Ma, Xiaodong Zhou, Wenhui Yu, Rong Rosenholm, Jessica M. Tian, Weizhong Zhang, Lirong Wang, Dongqing Zhang, Hongbo Pharmaceutics Article Pancreatic carcinoma is an aggressive subtype of cancer with poor prognosis, known for its refractory nature. To address this challenge, we have established a stable nanoplatform that combines chemotherapy with photodynamic therapy (PDT) to achieve better curative efficacy. First, we designed and synthesized a disulfide-bonded paclitaxel (PTX)-based prodrug, which was further mixed with gemcitabine (GEM) and photosensitizer THPP in an optimized ratio. Subsequently, the mixture was added dropwise into amphiphilic polymer DSPE-PEG water solution to form micelles composed of DSPE-PEG nanoparticles (TPG NPs). The TPG NPs were around 135 nm, and showed great ability of DTT stimulated release of PTX and GEM. Moreover, the TPG NPs can be efficiently uptaken by pancreatic cancer PANC-1 cells and effectively kill them, especially when combined with 650 nm laser irradiation. Finally, the TPG NPs have shown enhanced long-term circulation ability and also exhibited efficient anti-tumor activity in combination with 650 nm laser irradiation in a pancreatic cancer mouse model. In summary, the designed TPG NPs possesses great potential for co-delivery of paclitaxel prodrug, GEM and THPP, which enables combined chemo-photodynamic therapy for cancer treatment. In addition, the stimulated release of PTX prodrug and GEM also allows for better targeting of tumor cells and the increased therapeutic effect against cancer cells. Overall, the TPG NPs can serve as a good candidate for pancreatic cancer treatment. MDPI 2022-10-25 /pmc/articles/PMC9698062/ /pubmed/36365099 http://dx.doi.org/10.3390/pharmaceutics14112280 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wu, Qiwei
Ma, Xiaodong
Zhou, Wenhui
Yu, Rong
Rosenholm, Jessica M.
Tian, Weizhong
Zhang, Lirong
Wang, Dongqing
Zhang, Hongbo
Co-Delivery of Paclitaxel Prodrug, Gemcitabine and Porphine by Micelles for Pancreatic Cancer Treatment via Chemo-Photodynamic Combination Therapy
title Co-Delivery of Paclitaxel Prodrug, Gemcitabine and Porphine by Micelles for Pancreatic Cancer Treatment via Chemo-Photodynamic Combination Therapy
title_full Co-Delivery of Paclitaxel Prodrug, Gemcitabine and Porphine by Micelles for Pancreatic Cancer Treatment via Chemo-Photodynamic Combination Therapy
title_fullStr Co-Delivery of Paclitaxel Prodrug, Gemcitabine and Porphine by Micelles for Pancreatic Cancer Treatment via Chemo-Photodynamic Combination Therapy
title_full_unstemmed Co-Delivery of Paclitaxel Prodrug, Gemcitabine and Porphine by Micelles for Pancreatic Cancer Treatment via Chemo-Photodynamic Combination Therapy
title_short Co-Delivery of Paclitaxel Prodrug, Gemcitabine and Porphine by Micelles for Pancreatic Cancer Treatment via Chemo-Photodynamic Combination Therapy
title_sort co-delivery of paclitaxel prodrug, gemcitabine and porphine by micelles for pancreatic cancer treatment via chemo-photodynamic combination therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9698062/
https://www.ncbi.nlm.nih.gov/pubmed/36365099
http://dx.doi.org/10.3390/pharmaceutics14112280
work_keys_str_mv AT wuqiwei codeliveryofpaclitaxelprodruggemcitabineandporphinebymicellesforpancreaticcancertreatmentviachemophotodynamiccombinationtherapy
AT maxiaodong codeliveryofpaclitaxelprodruggemcitabineandporphinebymicellesforpancreaticcancertreatmentviachemophotodynamiccombinationtherapy
AT zhouwenhui codeliveryofpaclitaxelprodruggemcitabineandporphinebymicellesforpancreaticcancertreatmentviachemophotodynamiccombinationtherapy
AT yurong codeliveryofpaclitaxelprodruggemcitabineandporphinebymicellesforpancreaticcancertreatmentviachemophotodynamiccombinationtherapy
AT rosenholmjessicam codeliveryofpaclitaxelprodruggemcitabineandporphinebymicellesforpancreaticcancertreatmentviachemophotodynamiccombinationtherapy
AT tianweizhong codeliveryofpaclitaxelprodruggemcitabineandporphinebymicellesforpancreaticcancertreatmentviachemophotodynamiccombinationtherapy
AT zhanglirong codeliveryofpaclitaxelprodruggemcitabineandporphinebymicellesforpancreaticcancertreatmentviachemophotodynamiccombinationtherapy
AT wangdongqing codeliveryofpaclitaxelprodruggemcitabineandporphinebymicellesforpancreaticcancertreatmentviachemophotodynamiccombinationtherapy
AT zhanghongbo codeliveryofpaclitaxelprodruggemcitabineandporphinebymicellesforpancreaticcancertreatmentviachemophotodynamiccombinationtherapy